Demographical Characteristics and Medical History of Enrolled Participants Among Children and Adults
| Characteristic . | Overall . | Children . | Adults . |
|---|---|---|---|
| No. | 1473 | 485 | 988 |
| Status | |||
| Emergency room | 134 (9.1) | 74 (15.3) | 60 (6.1) |
| Hospitalized (non-ICU) | 380 (25.8) | 148 (30.5) | 232 (23.5) |
| ICU | 101 (6.9) | 91 (18.8) | 10 (1.0) |
| Outpatient | 858 (58.2) | 172 (35.5) | 686 (69.4) |
| Age, y | |||
| Mean (SD) | 26.66 (21.34) | 3.34 (4.1) | 38.11 (16.51) |
| Median (IQR) | 24.00 (5.00–41.00) | 2.00 (0.00–5.00) | 34.00 (24.00–49.00) |
| Categorical age, y | |||
| 0–5 | 383 (26.0) | 383 (79.0) | 0 (0.0) |
| 6–11 | 64 (4.3) | 64 (13.2) | 0 (0.0) |
| 12–17 | 38 (2.6) | 38 (7.8) | 0 (0.0) |
| 18–59 | 868 (58.9) | 0 (0.0) | 868 (87.9) |
| ≥60 | 120 (8.1) | 0 (0.0) | 120 (12.1) |
| Sex | |||
| Female | 895 (60.8) | 220 (45.4) | 675 (68.3) |
| Male | 578 (39.2) | 265 (54.6) | 313 (31.7) |
| Smoking history | |||
| Never smoked | 923 (62.7) | 361 (74.4) | 562 (56.9) |
| Passive smoker | 168 (11.4) | 120 (24.7) | 48 (4.9) |
| Current smoker | 211 (14.3) | 2 (0.4) | 209 (21.2) |
| Former smoker | 171 (11.6) | 2 (0.4) | 169 (17.1) |
| Coinfection | 301 (20.4) | 137 (28.2) | 164 (16.6) |
| Influenza | 55 (3.7) | 20 (4.1) | 35 (3.5) |
| Coronavirus | 79 (5.4) | 18 (3.7) | 61 (6.2) |
| Parainfluenza virus | 49 (3.3) | 27 (5.6) | 22 (2.2) |
| Respiratory syncytial virus | 61 (4.1) | 35 (7.2) | 26 (2.6) |
| Adenovirus | 44 (3.0) | 24 (4.9) | 20 (2.0) |
| Bordetella pertussis | 8 (0.5) | 7 (1.4) | 1 (0.1) |
| Metapneumovirus | 26 (1.8) | 10 (2.1) | 16 (1.6) |
| Mycoplasma pneumoniae | 7 (0.5) | 3 (0.6) | 4 (0.4) |
| Comorbidities | |||
| Asthma | 165 (11.2) | 45 (9.3) | 120 (12.1) |
| Cardiovascular disorders | 148 (10.0) | 19 (3.9) | 129 (13.1) |
| Congenital syndromes | 92 (6.2) | 89 (18.4) | 3 (0.3) |
| Received influenza vaccine | 131 (8.9) | 40 (8.2) | 91 (9.2) |
| Received pneumonia vaccine | 473 (32.1) | 332 (68.5) | 141 (14.3) |
| Current medications | |||
| Antibiotics | 669 (45.4) | 262 (54.0) | 407 (41.2) |
| Antihistamines | 364 (24.7) | 89 (18.4) | 275 (27.8) |
| Antipyretics | 386 (26.2) | 157 (32.4) | 229 (23.2) |
| Systemic steroids | 303 (20.6) | 86 (17.7) | 217 (22.0) |
| Death | 29 (2.0) | 6 (1.2) | 23 (2.3) |
| Characteristic . | Overall . | Children . | Adults . |
|---|---|---|---|
| No. | 1473 | 485 | 988 |
| Status | |||
| Emergency room | 134 (9.1) | 74 (15.3) | 60 (6.1) |
| Hospitalized (non-ICU) | 380 (25.8) | 148 (30.5) | 232 (23.5) |
| ICU | 101 (6.9) | 91 (18.8) | 10 (1.0) |
| Outpatient | 858 (58.2) | 172 (35.5) | 686 (69.4) |
| Age, y | |||
| Mean (SD) | 26.66 (21.34) | 3.34 (4.1) | 38.11 (16.51) |
| Median (IQR) | 24.00 (5.00–41.00) | 2.00 (0.00–5.00) | 34.00 (24.00–49.00) |
| Categorical age, y | |||
| 0–5 | 383 (26.0) | 383 (79.0) | 0 (0.0) |
| 6–11 | 64 (4.3) | 64 (13.2) | 0 (0.0) |
| 12–17 | 38 (2.6) | 38 (7.8) | 0 (0.0) |
| 18–59 | 868 (58.9) | 0 (0.0) | 868 (87.9) |
| ≥60 | 120 (8.1) | 0 (0.0) | 120 (12.1) |
| Sex | |||
| Female | 895 (60.8) | 220 (45.4) | 675 (68.3) |
| Male | 578 (39.2) | 265 (54.6) | 313 (31.7) |
| Smoking history | |||
| Never smoked | 923 (62.7) | 361 (74.4) | 562 (56.9) |
| Passive smoker | 168 (11.4) | 120 (24.7) | 48 (4.9) |
| Current smoker | 211 (14.3) | 2 (0.4) | 209 (21.2) |
| Former smoker | 171 (11.6) | 2 (0.4) | 169 (17.1) |
| Coinfection | 301 (20.4) | 137 (28.2) | 164 (16.6) |
| Influenza | 55 (3.7) | 20 (4.1) | 35 (3.5) |
| Coronavirus | 79 (5.4) | 18 (3.7) | 61 (6.2) |
| Parainfluenza virus | 49 (3.3) | 27 (5.6) | 22 (2.2) |
| Respiratory syncytial virus | 61 (4.1) | 35 (7.2) | 26 (2.6) |
| Adenovirus | 44 (3.0) | 24 (4.9) | 20 (2.0) |
| Bordetella pertussis | 8 (0.5) | 7 (1.4) | 1 (0.1) |
| Metapneumovirus | 26 (1.8) | 10 (2.1) | 16 (1.6) |
| Mycoplasma pneumoniae | 7 (0.5) | 3 (0.6) | 4 (0.4) |
| Comorbidities | |||
| Asthma | 165 (11.2) | 45 (9.3) | 120 (12.1) |
| Cardiovascular disorders | 148 (10.0) | 19 (3.9) | 129 (13.1) |
| Congenital syndromes | 92 (6.2) | 89 (18.4) | 3 (0.3) |
| Received influenza vaccine | 131 (8.9) | 40 (8.2) | 91 (9.2) |
| Received pneumonia vaccine | 473 (32.1) | 332 (68.5) | 141 (14.3) |
| Current medications | |||
| Antibiotics | 669 (45.4) | 262 (54.0) | 407 (41.2) |
| Antihistamines | 364 (24.7) | 89 (18.4) | 275 (27.8) |
| Antipyretics | 386 (26.2) | 157 (32.4) | 229 (23.2) |
| Systemic steroids | 303 (20.6) | 86 (17.7) | 217 (22.0) |
| Death | 29 (2.0) | 6 (1.2) | 23 (2.3) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
Demographical Characteristics and Medical History of Enrolled Participants Among Children and Adults
| Characteristic . | Overall . | Children . | Adults . |
|---|---|---|---|
| No. | 1473 | 485 | 988 |
| Status | |||
| Emergency room | 134 (9.1) | 74 (15.3) | 60 (6.1) |
| Hospitalized (non-ICU) | 380 (25.8) | 148 (30.5) | 232 (23.5) |
| ICU | 101 (6.9) | 91 (18.8) | 10 (1.0) |
| Outpatient | 858 (58.2) | 172 (35.5) | 686 (69.4) |
| Age, y | |||
| Mean (SD) | 26.66 (21.34) | 3.34 (4.1) | 38.11 (16.51) |
| Median (IQR) | 24.00 (5.00–41.00) | 2.00 (0.00–5.00) | 34.00 (24.00–49.00) |
| Categorical age, y | |||
| 0–5 | 383 (26.0) | 383 (79.0) | 0 (0.0) |
| 6–11 | 64 (4.3) | 64 (13.2) | 0 (0.0) |
| 12–17 | 38 (2.6) | 38 (7.8) | 0 (0.0) |
| 18–59 | 868 (58.9) | 0 (0.0) | 868 (87.9) |
| ≥60 | 120 (8.1) | 0 (0.0) | 120 (12.1) |
| Sex | |||
| Female | 895 (60.8) | 220 (45.4) | 675 (68.3) |
| Male | 578 (39.2) | 265 (54.6) | 313 (31.7) |
| Smoking history | |||
| Never smoked | 923 (62.7) | 361 (74.4) | 562 (56.9) |
| Passive smoker | 168 (11.4) | 120 (24.7) | 48 (4.9) |
| Current smoker | 211 (14.3) | 2 (0.4) | 209 (21.2) |
| Former smoker | 171 (11.6) | 2 (0.4) | 169 (17.1) |
| Coinfection | 301 (20.4) | 137 (28.2) | 164 (16.6) |
| Influenza | 55 (3.7) | 20 (4.1) | 35 (3.5) |
| Coronavirus | 79 (5.4) | 18 (3.7) | 61 (6.2) |
| Parainfluenza virus | 49 (3.3) | 27 (5.6) | 22 (2.2) |
| Respiratory syncytial virus | 61 (4.1) | 35 (7.2) | 26 (2.6) |
| Adenovirus | 44 (3.0) | 24 (4.9) | 20 (2.0) |
| Bordetella pertussis | 8 (0.5) | 7 (1.4) | 1 (0.1) |
| Metapneumovirus | 26 (1.8) | 10 (2.1) | 16 (1.6) |
| Mycoplasma pneumoniae | 7 (0.5) | 3 (0.6) | 4 (0.4) |
| Comorbidities | |||
| Asthma | 165 (11.2) | 45 (9.3) | 120 (12.1) |
| Cardiovascular disorders | 148 (10.0) | 19 (3.9) | 129 (13.1) |
| Congenital syndromes | 92 (6.2) | 89 (18.4) | 3 (0.3) |
| Received influenza vaccine | 131 (8.9) | 40 (8.2) | 91 (9.2) |
| Received pneumonia vaccine | 473 (32.1) | 332 (68.5) | 141 (14.3) |
| Current medications | |||
| Antibiotics | 669 (45.4) | 262 (54.0) | 407 (41.2) |
| Antihistamines | 364 (24.7) | 89 (18.4) | 275 (27.8) |
| Antipyretics | 386 (26.2) | 157 (32.4) | 229 (23.2) |
| Systemic steroids | 303 (20.6) | 86 (17.7) | 217 (22.0) |
| Death | 29 (2.0) | 6 (1.2) | 23 (2.3) |
| Characteristic . | Overall . | Children . | Adults . |
|---|---|---|---|
| No. | 1473 | 485 | 988 |
| Status | |||
| Emergency room | 134 (9.1) | 74 (15.3) | 60 (6.1) |
| Hospitalized (non-ICU) | 380 (25.8) | 148 (30.5) | 232 (23.5) |
| ICU | 101 (6.9) | 91 (18.8) | 10 (1.0) |
| Outpatient | 858 (58.2) | 172 (35.5) | 686 (69.4) |
| Age, y | |||
| Mean (SD) | 26.66 (21.34) | 3.34 (4.1) | 38.11 (16.51) |
| Median (IQR) | 24.00 (5.00–41.00) | 2.00 (0.00–5.00) | 34.00 (24.00–49.00) |
| Categorical age, y | |||
| 0–5 | 383 (26.0) | 383 (79.0) | 0 (0.0) |
| 6–11 | 64 (4.3) | 64 (13.2) | 0 (0.0) |
| 12–17 | 38 (2.6) | 38 (7.8) | 0 (0.0) |
| 18–59 | 868 (58.9) | 0 (0.0) | 868 (87.9) |
| ≥60 | 120 (8.1) | 0 (0.0) | 120 (12.1) |
| Sex | |||
| Female | 895 (60.8) | 220 (45.4) | 675 (68.3) |
| Male | 578 (39.2) | 265 (54.6) | 313 (31.7) |
| Smoking history | |||
| Never smoked | 923 (62.7) | 361 (74.4) | 562 (56.9) |
| Passive smoker | 168 (11.4) | 120 (24.7) | 48 (4.9) |
| Current smoker | 211 (14.3) | 2 (0.4) | 209 (21.2) |
| Former smoker | 171 (11.6) | 2 (0.4) | 169 (17.1) |
| Coinfection | 301 (20.4) | 137 (28.2) | 164 (16.6) |
| Influenza | 55 (3.7) | 20 (4.1) | 35 (3.5) |
| Coronavirus | 79 (5.4) | 18 (3.7) | 61 (6.2) |
| Parainfluenza virus | 49 (3.3) | 27 (5.6) | 22 (2.2) |
| Respiratory syncytial virus | 61 (4.1) | 35 (7.2) | 26 (2.6) |
| Adenovirus | 44 (3.0) | 24 (4.9) | 20 (2.0) |
| Bordetella pertussis | 8 (0.5) | 7 (1.4) | 1 (0.1) |
| Metapneumovirus | 26 (1.8) | 10 (2.1) | 16 (1.6) |
| Mycoplasma pneumoniae | 7 (0.5) | 3 (0.6) | 4 (0.4) |
| Comorbidities | |||
| Asthma | 165 (11.2) | 45 (9.3) | 120 (12.1) |
| Cardiovascular disorders | 148 (10.0) | 19 (3.9) | 129 (13.1) |
| Congenital syndromes | 92 (6.2) | 89 (18.4) | 3 (0.3) |
| Received influenza vaccine | 131 (8.9) | 40 (8.2) | 91 (9.2) |
| Received pneumonia vaccine | 473 (32.1) | 332 (68.5) | 141 (14.3) |
| Current medications | |||
| Antibiotics | 669 (45.4) | 262 (54.0) | 407 (41.2) |
| Antihistamines | 364 (24.7) | 89 (18.4) | 275 (27.8) |
| Antipyretics | 386 (26.2) | 157 (32.4) | 229 (23.2) |
| Systemic steroids | 303 (20.6) | 86 (17.7) | 217 (22.0) |
| Death | 29 (2.0) | 6 (1.2) | 23 (2.3) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ICU, intensive care unit; IQR, interquartile range; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
